


PHARMACEUTICAL 2022



Elicio Therapeutics Inc. Rank 206 of 466





PHARMACEUTICAL 2022



Elicio Therapeutics Inc. Rank 206 of 466

The relative strengths and weaknesses of Elicio Therapeutics Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Elicio Therapeutics Inc. compared to the market average is the variable Liabilities, Current, increasing the Economic Capital Ratio by 40% points. The greatest weakness of Elicio Therapeutics Inc. is the variable Research and Development, reducing the Economic Capital Ratio by 39% points.

The company's Economic Capital Ratio, given in the ranking table, is 154%, being 76% points above the market average of 78%.

Input Variable	Value in 1000 USD
Assets, Current	91,247
Cost of Goods Sold	433
Intangible Assets	0
Liabilities, Current	11,296
Liabilities, Non-Current	3,475
Other Assets	4,815
Other Compr. Net Income	230
Other Expenses	0
Other Liabilities	235
Other Net Income	-15,266
Other Revenues	28,312
Property and Equipment	451
Research and Development	48,698
Selling, General and Administrative Expense	18,488

Output Variable	Value in 1000 USD
Assets	96,513
Liabilities	15,006
Expenses	67,619
Revenues	28,312
Stockholders Equity	81,507
Net Income	-54,573
Comprehensive Net Income	-54,458
Economic Capital Ratio	154%

